FDA Clears Insulin Dose Adjustment (IDA) Feature of ALRT System
ALR Technologies announced the FDA granted clearance for an innovative insulin dose adjustment feature of the ALRT diabetes management system.
Your trusted source for investing success
Your trusted source for investing success
ALR Technologies announced the FDA granted clearance for an innovative insulin dose adjustment feature of the ALRT diabetes management system.
ALR Technologies announced the US Food and Drug Administration granted clearance for their innovative insulin dose adjustment (IDA) feature of the ALRT diabetes management system.
Attacks on medical devices is a growing problem, while the budget on medical device security is expected to reach $101 billion by 2018.
By Shelly Kumar
Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function.
The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose,
AntriaBio announced the dosing of the first patient in their Phase 1 first-in-human clinical trial of its lead product candidate, AB101.
AntriaBio filed an Investigational New Drug application with the FDA for their basal insulin treatment for diabetes mellitus patients. A trial is set to follow.
AntriaBio began engaging Prosciento to conduct a clinical study of AB101 for patients with diabetes mellitus.
We take a look at the latest medical device companies that received an FDA clearance, what their products are about and their stock performance.
PharmaCyte Biotech clinical stage biotechnology company announced a new side of the company by naming Dr. Mark L. Rabe as director of the cannabis development program.
XOMA (NASDAQ: XOMA) announced it will be showcasing preclinical data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting.
SQI Diagnostics (TSXV:SQD, OTCQX:SQIDF) has entered a partnership with a company in California to evolve their cardiac event prediction test.
Protext Mobility (OTC PINK:TXTM) discusses the potential of its main product Phytofare in treating type II Diabetes.
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third article in a series of Q&A articles that will be conducted with some of the key team members of PharmaCyte’s upcoming
Valeritas Holdings (OTCQB:VLRX) today announced data showing greater reductions in A1c and insulin dose in patients with type 2 diabetes who used V-Go® Wearable Insulin Delivery device compared to patients using insulin pen devices. The data were presented as an E-Poster at The 10th International Conference on Advanced Technologies &
Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian subsidiary, Orgenesis SPRL, has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budget of EUR 12.3 million ($12.8 million) support program for the GMP
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the U.S.
Eternity Healthcare Inc. (OTC:ETAH), announces first regulatory approval of its Loader for the Lenis® Needle-Free Injection system.
“CE Certification opens the door for regulatory approval in the EU as well as other countries that follow the EU. With the most difficult components already certified, we remain confident the final two certifications
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on
From cybersecurity to bioelectronics, medical device topics are garnering increased media coverage.
